Anna Fritschen
Papers
2
Total Citations
38
H-Index
2
About
Dr. Anna Fritschen is a pioneer at the intersection of 3D bioprinting and microfluidic organ-on-a-chip (OOC) technology, driving the field from proof-of-concept toward scalable, automated biomanufacturing. Her research centers on engineering high-throughput platforms that can fabricate vascularized, physiologically relevant tissue models for pharmaceutical testing. In her landmark 2024 paper—already garnering 31 citations—she introduced a high-scale bioprinting platform capable of automating the production of vascularized OOCs, addressing a critical bottleneck in translating these models from academic labs to commercial drug development pipelines. Complementing this, her work on a robotic-assisted handling and manipulation system (7 citations) tackles the challenge of reliable, high-volume bioproduction, a key step toward market viability. Dr. Fritschen’s contributions are particularly notable for merging precision engineering with biological complexity, enabling the creation of multi-organ chips that more accurately mimic human physiology. Her achievements position her as a leading voice in the next wave of biomedical engineering, where automation and scalability are transforming how we study disease and test therapeutics.
Research Focus
Key Achievements
Top Papers
- 1
- 2